Sodium StibogluconateThird Party Manufacturing in India

Sodium Stibogluconate works as a pentavalent antimonial compound that exerts its antileishmanial effect through multiple mechanisms. It is thought to act as a prodrug that is converted intracellularly to the more active trivalent antimony form within the Leishmania parasite and in the acidic compartments of macrophages.

The active trivalent antimony binds to sulfhydryl-containing biomolecules including trypanothione, a key thiol in Leishmania parasites, disrupting the parasite's antioxidant defense system. It also inhibits parasitic type I DNA topoisomerase, interfering with DNA replication and repair. Additionally, Sodium Stibogluconate modulates the host immune response by inhibiting protein tyrosine phosphatases such as SHP-1 and SHP-2, leading to enhanced cytokine signaling and macrophage activation.

Unlike many other antiprotozoal agents, Sodium Stibogluconate combines direct parasiticidal activity with host immune modulation. It is highly effective against visceral leishmaniasis, cutaneous leishmaniasis, and mucocutaneous leishmaniasis, and remains a WHO-recommended first-line treatment in many endemic regions.

Therapeutic Uses

Sodium Stibogluconate is prescribed for the treatment of:

• Visceral Leishmaniasis (Kala-azar): First-line treatment for systemic Leishmania donovani infection affecting the spleen, liver, and bone marrow.
• Cutaneous Leishmaniasis: Treatment of skin ulcers caused by Leishmania species, including Leishmania tropica and Leishmania major.
• Mucocutaneous Leishmaniasis: Management of destructive lesions of the nasopharyngeal mucosa caused by Leishmania braziliensis complex.
• Post-Kala-azar Dermal Leishmaniasis: Treatment of skin manifestations that can follow visceral leishmaniasis.

Why Manufacturers Choose Sodium Stibogluconate

Leishmaniasis remains a significant public health problem in tropical and subtropical regions, with millions at risk worldwide. Sodium Stibogluconate, marketed historically as Pentostam, has been in continuous clinical use for over half a century and is included in the WHO Essential Medicines List. Despite newer therapies, it remains indispensable for endemic regions in the Indian subcontinent, East Africa, and Latin America.

This makes Sodium Stibogluconate an essential antiprotozoal for third party manufacturing in India, serving WHO treatment programs and export to endemic countries with ongoing disease burden.